



PHILIPPINE MEDICAL ASSOCIATION

THEME: "BUILD, BUILD, BUILD PMA!"

Member : World Medical Association (WMA)
Co-Founder : Confederation of Medical Association in Asia and Oceania (CMAAO)
Medical Association of Southeast Asian Nations (MASEAN)
Secretariat : Philippine Medical Association Building, North Avenue, Quezon City 1105
Telephone Numbers: (632) 929-7361; 929-6366; 926-2447 Fax: (632) 929-6951
Mobile Numbers: 0927-5806903; 0947-2994782 (Membership)
0917-8221357; 0918-9234732 (Secretariat)
Email: philmedas@yahoo.com; philmedas@gmail.com; info@philippinemedicalassociation.org
Website: www.philippinemedicalassociation.org

NATIONAL OFFICERS 2018-2019

JOSE P. SANTIAGO JR., MD
President

BENITO P. ATIENZA, MD
Vice President

CHRISTINE S. TINIO, MD
National Treasurer

BENJAMIN M. ALABAN, MD
Secretary General

BOARD OF GOVERNORS

MARTIN HEGINIO C. QUERUBIN, MD
Northeastern Luzon

FELIPE GOZAR L. DUQUE, MD
Northwestern Luzon

WILFREDO F. BATOL, MD
Central Luzon

ALEJANDRO Y. TAN, MD
Manila

NORMA M. TORREGOZA, MD
Quezon City

CORAZON E. LEYVA, MD
Rizal

JOSE FLORENCIO F. LAPEÑA JR., MD
Central Tagalog

NILO M. ALCOREZA, MD
Southern Tagalog

MA. HUMILDE B. JANABAN, MD
Bicol

ERLINDA G. DE LOS REYES, MD
Western Visayas

MARLON T. CO, MD
Central Visayas

REALINO G. MOLINA, MD
Eastern Visayas

APRIL R. LOPEZ, MD
Western Mindanao

DURES FE E. TAGAYUNA, MD
Northern Mindanao

DANTE T. EUGENIO, MD
Southeastern Mindanao

GRACE MARILOU L. VEGA, MD
Northcentral Mindanao

ADAH JUNE C. ROBLES, MD
Caraga

MEMORANDUM CIRCULAR NO: 2018-09-10-025

**TO : BOARD OF GOVERNORS
ALL PRESIDENTS OF:
COMPONENT SOCIETIES
SPECIALTY DIVISIONS
SPECIALTY SOCIETIES
AFFILIATE SOCIETIES**

DATE : SEPTEMBER 10, 2018


SUBJECT : ADVISORY FROM DANGEROUS DRUGS BOARD

Greetings from the Philippine Medical Association!

Please be informed of the advisory that was released last September 4, 2018, from Secretary Catalino Cuy, Chair of the Dangerous Drugs Board, addressed to all physicians, dentists, veterinarians, and pharmacists, regarding the USE OF ORDINARY PERSONALIZED PRESCRIPTION FORM IN LIEU OF THE SPECIAL PRESCRIPTION FORM FOR DANGEROUS DRUGS (SPFDD).

Kindly see attached document for your reference. Thank you.

Very truly yours,


BENJAMIN M. ALABAN, MD
Secretary General

Noted by:


JOSE P. SANTIAGO JR., MD
President



Republic of the Philippines
Office of the President
DANGEROUS DRUGS BOARD

ADVISORY

TO : ALL PHYSICIANS, DENTISTS, VETERINARIANS AND PHARMACISTS

**FROM : SECRETARY CATALINO S. CUY
CHAIRMAN**

**SUBJECT : USE OF ORDINARY PERSONALIZED PRESCRIPTION FORM IN
LIEU OF THE SPECIAL PRESCRIPTION FORM FOR DANGEROUS
DRUGS (SPFDD)**

DATE : 04 SEPTEMBER 2018

In the interest of public service, please be informed that due to the unavailability of the Special Prescription Form for Dangerous Drugs (SPFDD) known as "Yellow Prescription Form," the Dangerous Drugs Board hereby allows the use of ORDINARY PERSONALIZED PRESCRIPTION FORM IN TRIPLICATE COPY to be used by Medical Practitioners with updated PDEA S2 License in prescribing dangerous drugs for their patients until 04 October 2018 or until such time that the SPFDD becomes available.

The prescription shall contain only one (1) dangerous drug with the following information:

- a. the full name, complete business address, telephone number/email address, current S-2 License number, validity of license, and Professional Tax Receipt of the prescribing practitioner;
- b. complete name, age, and complete address of the patient;
- c. date of the prescription;
- d. generic and brand name of the preparation to be supplied, its dosage strength and form;
- e. the total number of dosage units or total quantity of preparation to be supplied in words and its numerical equivalent;
- f. specific direction of use; and
- g. original signature of the medical practitioner.

Further, the same shall be in triplicate copy, the original copy of which shall be surrendered to the drugstore or pharmacy that dispensed the dangerous drug; the duplicate copy shall remain with the patient or purchaser-representative, and the triplicate copy shall be retained by the prescribing practitioner.

This advisory shall take effect immediately.


SECRETARY CATALINO S. CUY
Chairman

